Further interrogation of this phenomenon revealed that EMT6 tumors, even in the absence of M7824 treatment, are highly susceptible to CD4 depletion, as 90% of PBS-treated mice underwent complete tumor rejection when CD4+ T cells were depleted (Supplementary Figure 4E-G). This evidence concerns the gene CD4 and neoplasm.